
Novel мощный and balanced dual CDK6/PIM1 ингибитор, showing high киназы selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo
Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.